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Abstract
We present the case of an 80 year-old female patient with pulmonary arterial hypertension of complex aetiology, 
including late-diagnosed congenital heart disease. We describe the diagnostic procedures and staged treatment (per-
cutaneous closure of an ostium secundum atrial septal defect and drug treatment with riociguat) which resulted in 
a significant clinical improvement.
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Introduction
Pulmonary hypertension leads to a significant impairment 
of exercise tolerance and is associated with adverse 
long-term outcomes [1]. The aetiology of pulmonary hy-
pertension is not always clear and may be multifactorial, 
as exemplified by the case reported below. In addition, 
increasing rates of a complex aetiology of this condition 
may be expected with an ageing population.
Case report
An 80 year-old woman was admitted on an elective basis to 
our Department of Cardiology in May 2017 due to worsening 
exercise tolerance that had progressed gradually over se-
veral years (in the weeks prior to the admission, dyspnoea 
developed after walking 50 metres). Past medical history 
included permanent atrial fibrillation, chronic hepatitis C 
(without evidence of cirrhosis or portal hypertension in 
imaging studies), and cholecystectomy in 2008. Pulmonary 
computed tomographic angiography (angio-CT) performed 
on an outpatient basis showed no evidence of pulmonary 
embolism. Chronic medications included acenocoumarol, 
metoprolol succinate 50 mg/day, spironolactone 25 mg/ 
/day, and valsartan 80 mg/day.
On admission, the patient was in general good condi-
tion, with irregular heart rate of 112 bpm, blood pressure 
of 120/70 mm Hg, and mild calf oedema with evidence of 
post-thrombotic syndrome. Deep venous thrombosis was 
excluded based on Doppler ultrasonography of the lower limb 
veins. Echocardiography showed an increased right atrial 
area (RAA) of 40 cm2 and an enlarged right ventricle (RV), 
with right ventricular diameter (RVID) in the 4-chamber view 
of 5.4 cm compared to 4.9 cm for the left ventricle, impaired 
RV systolic function with the tricuspid annular plane systolic 
excursion (TAPSE) of 14 mm, increased RV systolic pressure 
(RVSP; 67 mm Hg), and a dilated vena cava inferior (29 mm) 
with reduced respiratory variation. Left ventricular function 
was normal. Laboratory tests showed elevated levels of total 
bilirubin (1.76 mg/dL) and B-type natriuretic peptide (BNP: 
324 pg/mL). The 6-minute walking test result was 190 me-
tres, without a reduction in oxygen saturation. Right heart 
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catheterisation showed precapillary pulmonary hypertension 
with increased mean pulmonary artery pressure (mPAP) 
of 32 mm Hg and pulmonary vascular resistance (PVR) of 
3.2 Wood units, with normal pulmonary capillary wedge pres-
sure (PCWP) of 14 mm Hg. The mean right atrial pressure 
(RAP) was 9 mm Hg, cardiac index (CI) was 2.91 L/min/m2, 
and RV oxygen saturation was 84%. No significant changes 
in these parameters were seen following iloprost administra-
tion (inhaled). Routine diagnostic evaluation of pulmonary 
hypertension included transoesophageal echocardiography 
which showed an ostium secundum-type atrial septal defect 
(ASD II) with the dimensions of 16 × 12 mm with a left-to-
-right shunt. Lung scintigraphy revealed high probability of 
pulmonary embolism, and invasive arteriography showed 
thrombi in distal branches of pulmonary arteries, mainly in 
the lower lobes of both lungs.
Based on the overall clinical presentation and imaging 
findings, pulmonary hypertension of mixed aetiology was 
diagnosed: chronic thromboembolic pulmonary hyperten-
sion (CTEPH) combined with a congenital heart disease 
(ASD II). At the meeting of a CTEPH heart team that included 
a cardiac surgeon and an invasive cardiologist experienced 
in pulmonary artery balloon angioplasty, the patient was 
not deemed a candidate for invasive treatment of CTEPH 
due to distal changes in pulmonary arteries. Drug treat-
ment with torasemide 10 mg/day and sildenafil 25 mg TID 
was started, initially with a subjective improvement in the 
patient’s wellbeing.
After six months, the patient was readmitted in No-
vember 2017 for a follow-up cardiac catheterisation which 
showed an increase in mPAP to 44 mm Hg, with PVR of 
4.06 Wood units and PCWP of 12 mm Hg (Table 1). These 
Table 1. Clinical characteristics of the patient at follow-up visits
May 2017 
Before initiation 
of sildenafil
November 2017 
Sildenafil  
treatment
June  2018 
After ASD II  
closure
September 2018 
Riociguat  
treatment
March 2019 
Riociguat  
treatment
WHO/NYHA class III/IV III III III II/III
6-minute walking test [m] 190 162* 250 270
Laboratory tests:
• haemoglobin [g/dL]
• creatinine [mg/dL]
• total bilirubin [mg/dL]
• BNP [pg/mL]
13.0
0.73
1.76
324
12.6
0.81
270
12.2
0.9
1.81
290
12.8
0.82
1.17
136
13.2
0.9
1.04
146
Echocardiography:
• RV:LV [mm]
• RAA [cm2]
• LAA [cm2]
• TI Vmax [m/s]
• RVSP [mm Hg]
• VCI [mm]
• TAPSE [mm]
54:49
40
44
3.9
67
29/20
14
50:53
36
38.1
3.4
55
21/10
18
41:52
31.3
39
2.6
32
15/9
18
Cardiac catheterisation:
• mRAP [mm Hg]
• mPAP [mm Hg]
• PCWP [mm Hg]
• CI [L/min/m2]
• PVR [Wood units]
9
32
14
2.91
3.2
20
44
12
2.27
4.06
6
32
10
2.29
5.51
*Distance limited by knee pain; ASD II — secundum-type atrial septal defect; WHO — World Health Organization; HYHA — New York Heart Association; BNP — B-type natriuretic peptide; RV:LV — right ventri-
cular to left ventricular diameter ratio in the apical 4-chamber view; RAA — right atrial area; LAA — left atrial area; TI Vmax — peak tricuspid regurgitant jet velocity; RVSP — right ventricular systolic pressure; 
VCI — vena cava inferior diameter/respiratory variability; TAPSE — tricuspid annular plane systolic excursion; mRAP — mean right atrial pressure; mPAP — mean pulmonary artery pressure; PCWP — pulmonary 
capillary wedge pressure; CI — cardiac index; PVR — pulmonary vascular resistance
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findings were interpreted as resulting from an increased 
shunt through ASD (sildenafil reduced PVR, which led 
to an increase in the left-to-right shunt). Due to severe 
exertional dyspnoea, a follow-up 6-minute walking test 
was not performed. BNP level was 270 pg/mL. Pulmonary 
angio-CT showed no evidence of pulmonary embolism. 
Sildenafil was withdrawn, and the patient was referred 
for ASD closure.
That procedure was performed in January 2018 with 
local anaesthesia via the right femoral vein access, using 
the Figulla Flex II ASD 24 mm device with good immediate 
procedural outcomes. In addition to acenocoumarol, ace-
tylsalicylic acid was prescribed for six months.
In June 2018, follow-up right heart catheterisation sho-
wed mPAP of 32 mm Hg, PVR of 5.51 Wood units, PCWP of 
10 mm Hg, RAP of 6 mm Hg, and CI of 2.29 L/min/m2. The 
6-minute walking test result was only 162 metres, but this 
was related to pain in the right knee felt by the patient. Total 
bilirubin level was 1.81 mg/dL, and BNP level was 290 pg/ 
/mL. The patient was put on riociguat treatment under the 
National Health Fund programme for CTEPH.
Riociguat is a soluble guanylate cyclase stimulator 
which increases cyclic guanosine monophosphate (cGMP) 
production and sensitises guanylate cyclase to endogenous 
nitric oxide [2]. As a result, the arteries and pulmonary 
arterioles dilate, and this mechanism is responsible for the 
reduction of pulmonary artery pressure and improvement 
of exercise tolerance. Drug efficacy has been supported by 
the results of several clinical trials [3, 4].
In our patient, riociguat treatment was started in July 
2018, and the dose was gradually increased to the target 
dose of 2.5 mg TID. Diuretic treatment was continued 
(torasemide 20 mg, spironolactone 50 mg) but due to 
bradycardia on 48-hour ECG Holter monitoring and low 
systemic blood pressure values, beta-blocker dose was 
reduced and valsartan was withdrawn.
Follow-up echocardiography in September 2018 showed 
persistent right heart chamber enlargement (RAA 36 cm2, 
RVID 50 mm). RVSP was 55 mm Hg but RV systolic function 
was normal, with TAPSE of 18 mm and the systolic velocity 
of RV free wall in spectral tissue Doppler of 13 cm/s. The 
vena cava inferior was not widened, with preserved respi-
ratory variability, and no shunt was seen at the atrial septal 
occluder. Following riociguat treatment, a significant subje-
ctive improvement was accompanied by an increase in the 
6-minute walking distance to 270 metres, and laboratory 
tests showed reductions of total bilirubin level to 1.04 mg/ 
/dL and BNP level to 146 pg/mL Echocardiography in April 
2019 showed a significant decrease in RVSP (40 mm Hg), 
reductions of right atrial and RV diameter (31 cm2 and 
47 mm, respectively), and  normal RV systolic function.
Conclusions
Our case highlights the importance of multifactorial 
aetiology of pulmonary hypertension. Staged therapeutic 
strategy targeted at various aetiological mechanisms of 
pulmonary hypertension led to a gradual improvement of 
the clinical condition along with cardiac catheterisation, 
echocardiographic, and laboratory parameters. It is worth 
noting that the initial deterioration of the patient’s condi-
tion was related to sildenafil treatment which resulted in 
worsening of the left-to-right shunt. It was only after ASD 
II closure that effective treatment with riociguat, a drug 
with a similar mechanism of action to sildenafil, was pos-
sible. The procedural success of ASD closure changed the 
pathophysiology of the condition, allowing drug-related 
haemodynamic improvement.
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Streszczenie
W pracy zaprezentowano przypadek 80-letniej pacjentki z tętniczym nadciśnieniem płucnym o złożonej etiologii, w tym 
z powodu późno rozpoznanej wrodzonej wady serca. Opisano diagnostykę oraz etapowe leczenie (przezskórne zamknię-
cie ubytku przegrody międzyprzedsionkowej typu II oraz farmakoterapia riociguatem), które przyniosły istotną poprawę 
kliniczną.
Słowa kluczowe: nadciśnienie płucne, ubytek przegrody międzyprzedsionkowej, zakrzepowo-zatorowe nadciśnienie 
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